Cyclacel Pharmaceuticals, Inc. (CYCC) financial statements (2020 and earlier)

Company profile

Business Address 200 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12131518181920
Cash and cash equivalents12131518181920
Receivables    0 0
Prepaid expense1   1  
Deposits current assets    0  
Other current assets0000000
Other undisclosed current assets1332123
Total current assets:14161820202123
Noncurrent Assets
Operating lease, right-of-use asset11  
Property, plant and equipment0000000
Other undisclosed noncurrent assets  11   
Total noncurrent assets:1111000
TOTAL ASSETS:15171922202123
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2232444
Accounts payable1111312
Accrued liabilities2111232
Total current liabilities:2232444
Noncurrent Liabilities
Long-term debt and lease obligation11     
Operating lease, liability11  
Other undisclosed noncurrent liabilities  11000
Total noncurrent liabilities:1111000
Total liabilities:4344544
Stockholders' equity
Stockholders' equity attributable to parent12141618151719
Common stock0000000
Additional paid in capital370370370370366365365
Accumulated other comprehensive loss(1)(1)(1)(1)(1)(1)(1)
Accumulated deficit(358)(355)(353)(352)(350)(348)(346)
Total stockholders' equity:12141618151719
TOTAL LIABILITIES AND EQUITY:15171922202123

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues    0 0
Other operating income      0
Cost of revenue
(Other undisclosed Cost of revenue)
(0)      
Gross profit:(0)     0
Operating expenses(3)(2)(2)(2)(3)(2)(2)
Other undisclosed operating income (loss)    0 (0)
Operating loss:(3)(2)(2)(2)(2)(2)(2)
Nonoperating income0000000
Investment income, nonoperating0000000
Foreign currency transaction gain (loss), before tax(0)000(0)0(0)
Other nonoperating income000 0 0
Loss from continuing operations before income taxes:(3)(2)(2)(2)(2)(2)(2)
Income tax benefit0000001
Net loss attributable to parent:(2)(2)(2)(2)(2)(2)(2)
Preferred stock dividends and other adjustments(0)(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(2)(2)(2)(2)(2)(2)(2)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(2)(2)(2)(2)(2)(2)(2)
Comprehensive loss:(2)(2)(2)(2)(2)(2)(2)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)(0)(0)000
Comprehensive loss, net of tax, attributable to parent:(2)(2)(2)(2)(2)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: